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Abstract 
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) entails long-term morbidities that 
impair survivors’ quality of life through broad physical and psychosocial sequelae. Current data and 
survival measurements maybe inadequate for contemporary Australian allo-HSCT recipients. This 
study sought to comprehensively describe survivorship in an up-to-date, local setting through 
validated measurements and a novel questionnaire designed to complement and address limitations 
of current instruments.  All adults who received an allo-HSCT between 2000 and 2012 in New South 
Wales were eligible and included if alive, literate, and consented to the study, which encompassed 7 
survey instruments. Four hundred and forty-three survivors participated; which is 76% of 
contactable (n=583) and 66% of eligible survivors (n= 669). Chronic graft-versus-host-disease 
(cGVHD) and comorbidities rates were similar to published data. Noteworthy results include 
prevalent sexual dysfunction (66% females, 52% males), loss of income (low income increased from 
21% to 36%, P<0.001) and employment (full-time employment fell from 64% to 33%, P<0.001), 
suboptimal vaccination (31% complete) and health screening (≈50%). Risk factors for poor 
vaccination and health screening were cGVHD, younger age, less education, rural/regional residence 
and transplantation <2 years. This study suggests that improvement in survivorship may necessitate 
structural changes in the current delivery of health services. 
Keywords: allogeneic transplant, long term follow-up, survival, survivorship, quality-of-life, 
psychosocial, multidisciplinary  
 
Introduction  
Over the past two decades advances in allogeneic haematopoietic stem cell transplantation (allo-
HSCT) have led to concomitant increases in the number of people undergoing this procedure and 
improvement in survivorship. Between 2001–2011, 90,000 allo-HSCTs were performed globally (1), 
with 4,369 of these performed in Australia (2) .  With improvements in donor selection, conditioning 
therapies and supportive care, more recipients are living longer (3), and up to 85% are expected to 
be alive at 10 years (4, 5).  
But while allo-HSCT provides a clear benefit, it is associated with significant morbidity and mortality 
(6). A range of complications may occur anytime post-transplant, including ‘early’ (<3 months), 
‘delayed’ (3mths to 2 years), ‘late’ (2-10 years) and ‘very late’ (>10 years) (7). Although 
contemporary allo-HSCT recipients are living longer than historical cohorts, published data suggests 
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that allo-HSCT survivors experience a 30% lower life expectancy than a matched population (6) and 
may experience a compromised quality of life due to the ongoing physical and psychological 
sequelae of cumulative therapies (8, 9), failure to reintegrate socially (10, 11), and uncertainty of 
prognosis (12).  
International and local bodies have recognised that research into the health, psychological and 
functional status of survivors is necessary to identify and address unmet needs of survivors and their 
families, enable better education and decision-making around BMT and inform the design and 
delivery of multidisciplinary health services essential to the care of long-term survivors(13-15). This 
provides the rationale both for international and national registry studies of survivorship and ‘local’ 
studies of the specific experience of allo-HSCT survivors.   
This study sought to comprehensively describe contemporary allo-HSCT survivorship in an Australian 
population with the intention of providing up-to-date information to candidates for allo-HSCT 
patients, their families and/or guardians regarding the long term sequelae of allo-HSCT, supporting 
local clinical and health policy decision-making around allo-HSCT and optimising the care of 
survivors. Specifically, the aims of this study were to document the incidence and range of late 
complications and their association with the health and functional status of allo-HSCT survivors, 
address limitations in the current literature around survivorship, particularly with regards to the 
financial, occupational and psychosocial impact of allo-HSCT, and identify gaps in the existing care of 
survivors in New South Wales (NSW), Australia.    
Methods 
Patients and procedures 
Participants were eligible if they had undergone an allo-HSCT between 1st January 2000 and 31st 
December 2012 in NSW, Australia’s most populous state (population 7.5 million)(16), were >18 years 
of age at time of transplant, literate in English and were alive at the time of sampling.  Potential 
participants’ identity and phone number were retrieved from the 4 NSW adult allogeneic transplant 
centres’ databases. Patients were informed about the study in a clinic visit or via a telephone call 
from one the researchers. Patients who agreed received a study pack at the clinic or through the 
post, which consisted of an invitation letter, patient information sheet, consent form, the 
questionnaire, and a stamped self-addressed envelope for return of the study instrument.  All 
participants were given the option to self-complete the questionnaire or via a phone interview with 
a researcher.  To increase recruitment, a second phone call was made to participants who had not 
returned the survey within a month.  This study was approved by the Northern Sydney Local Health 
District Research Ethics Committee (NSLHD Reference: 1207-217M). 
Instruments 
Researchers collated information from transplant databases on diagnosis, disease status and date of 
transplantation, conditioning regimen, GVHD prophylaxis, stem cell source and donor type for each 
consenting participant. All other information was obtained from patient’s self-reported responses to 
the questionnaire.   Participants completed a 20-page document that amalgamated 7 survey 
instruments; The Sydney Post BMT Study survey (SPBS) – a questionnaire uniquely developed by the 
research team – and 6 other instruments previously validated in allo-HSCT populations including the 
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Functional Assessment of Cancer Therapy – Bone Marrow Transplant (FACT-BMT Version 4) (17, 18), 
the Chronic GVHD Activity Assessment – Patient Self Report (Form B) (19), the Lee Chronic GVHD 
Symptom Scale (20), the Depression Anxiety and Stress Scale (DASS21) (21), the Post Traumatic 
Growth Inventory (PTGI) (22), and the Fear of Recurrence Scale (23).  
The Sydney Post BMT Study survey (SPBS) was uniquely designed by the research team to address 
limitations in existing post-transplant assessments to provide a more comprehensive account of 
survival. Item construction was informed by a review of the literature, interdisciplinary collaboration 
among health professionals involved in long-term care of allo-HSCT survivors and consultation with 
transplant recipients and their carers. There were 402 questions covering 20 domains including; 
demographics, medical complications, referrals/investigations, pharma- and non-pharmacotherapy, 
oral/dental health, infections, vaccinations, complementary therapy, cancer screening, travel 
history, close personal contacts, lifestyle, nutrition, infection risk, work status, fertility and sexual 
function, relationships, long-term follow-up (LTFU) care, psychosocial concerns, and a qualitative 
question  ‘What are the three things that have impacted you most?’.  The questionnaire used tick 
box response, short answer questions and 5-step Likert Scale measuring attitudes and other factors.  
The questionnaire was piloted in clinic and phone interviews to assess face and content validity and 
to check for comprehension of the survey questions.   
Statistical Analysis 
Exploratory analyses of all demographic data, baseline transplant characteristics, and post transplant 
exposures and life style factors were summarised using descriptive statistics.  Categorical responses 
were summarised using frequencies and percentages. Parametric continuous variables were 
summarised using means and standard deviations, and non-parametric variables using medians and 
interquartile ranges.  The Pearson Chi-square or Fishers’ Exact tests were used for dichotomous 
categorical variables and Pearson’s correlation coefficient to assess the relationships between 
continuous variables. The McNemar test was used to assess for significant differences in the 
distribution of pre and post-transplant dichotomous variables. Comparisons of means and medians 
were determined by the independent t-test and Wilcoxon Rank Sum tests for 2 samples; one way 
analysis of Variance (ANOVA) and Kruskal Wallis tests were used when there were >2 samples. 
Multivariable logistic regression was used to assess for significant associations between explanatory 
and outcome variables after adjusting for potential confounders.  A two-tailed P value <0.05 was 
considered as the level of statistical significance. 
Statistical analysis was performed using STATA 12.1 statistical package (StataCorp, USA).  
Results 
There were 1,475 allo-HSCT performed during the study period.  There were 669 recipients alive at 
study sampling.  Of the survivors, 583 were contactable and were sent study packs.  Surveys were 
completed and returned by 443 (66%); while 17 (3%) declined consent and 125 (21%) did not return 
the survey.  
Demographics and transplant characteristics are summarized in Table 1.  
Post allo-HSCT morbidities are detailed for cGVHD (Table 2), chronic morbidities including secondary 
malignancies (Table 3), and infectious disease (Supplementary Table 1). Summarily; cGVHD was 
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common (69.3%) and self reported symptoms were moderate-severe in 32.4%. Skin, eye, vagina and 
mouth were the most symptomatic. The most reported chronic morbidities following allo-HSCT were 
iron overload (32.5%), osteoporosis/osteopenia (29.1%), hypertension (28.9%) and cataracts 
(28.9%). Depression and anxiety were reported by 23.3% and 20.6%, respectively. The most 
frequently reported infections were influenza (38.4%) and herpes zoster (27.9%). A diagnosis of one 
or more malignancies following allo-HSCT was reported by 24%. The odds for having chronic 
comorbidities were compared between those who have cGVHD (n=301) and those without cGVHD 
(n=133)(Supplementary Table 2). cGVHD increased the odds of comorbidities, most significantly for 
osteoporosis/osteopenia (OR 1.85, P=0.01), cataracts (OR 2.26, P=0.001), recurrent upper 
respiratory tract infections (OR 1.86, P=0.02), diabetes mellitus (OR 2.10, P=0.03) and anxiety (OR 
1.86, P=0.03).  
Vaccination and health screening uptake are described in Table 4. Assessed screening were the 
Australian Government’s Department of Health national screening for breast carcinoma (women 50-
74 years), cervical (sexually active women between 18-70 years) and bowel carcinoma (>50 years). 
Briefly, 52.3% had skin checks, 63.4% and 53.3% of females had papanicolaou (PAP) smear and 
mammography, respectively, and 66% had regular dental reviews. Only 31.8% had completed 
transplant vaccinations recommended in the first 12 months post-transplant. Allo-HSCT of >2 years 
was the only variable significantly different between survivors who were not at all vaccinated 
compared to those who received all inactivated vaccines; survivors >2 years post allo-HSCT were 
much more likely to be vaccinated than early survivors (adjusted OR 12.2, 95% confidence interval 
3.1-49.0, P=0.001).  Age (P=0.93), gender (P=0.11), income (P=0.9), rural residence (P=0.71), marital 
status (P=0.26), education (P=0.31) and cGVHD (P=0.21) had no effect on vaccination.  Polypharmacy 
was common, 10% were on 5, and 21% were on 6 or more medications; Supplementary Table 3 
details medication use. 
Sexual dysfunction in allo-HSCT survivors was common. While similar percentages of males and 
females resumed sexual activity post-transplant (males 69.2%, females 68.5%), both genders 
reported high incidences of sexual difficulties. Two thirds of females (66.4%) and half of males 
(51.5%) reported any sexual dysfunction. Being female increased the risk of post-transplant sexual 
dysfunction (OR 1.8, P=0.01), particularly for decreased pleasure (OR 4.3, P<0.0001), libido (OR 1.4, 
P=0.002) and dyspareunia (OR 26.1, P<0.0001). Erectile dysfunction was reported by 76.6% of males 
with sexual difficulties.  
Specialist medical referrals were common (89%), and the median number of specialty services 
referred was three. The commonest were dermatology (60.3%), ophthalmology (43.6%), respiratory 
(28.2%) and endocrinology (23%). Allied health care referrals were less, with 41% reporting follow-
up with at least one allied health specialty; most commonly physiotherapy (24%), dietetics (23%) and 
clinical psychology (18%). Three quarters (74.4%) of survivors expressed a preference for LTFU 
through their transplant centres or a facility linked with their transplant centre including a satellite 
clinic or telemedicine facility, while a quarter preferred their primary/local haematologist or general 
practitioner.   
Four hundred and twenty-one respondents reported household income before and following allo-
HSCT. The proportion of those in the lowest household income strata increased from 21% pre-
transplant to 36% post-transplant (McNemar

2=46.3, P<0.001) (Figure 1a). Pre- and post-transplant 
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employment status was reported by 404 patients. Two-hundred and sixty one (65%) were in full time 
employment pre-transplant, which fell to 130  (32.5%) following allo-HSCT (McNemar 

2=106.6 , 
P<0.001). Importantly, ill-health as a cause for being unable to work increased from 3.4% prior to 
allo-HSCT to 13.8% after (McNemar 

2 =33.0 P<0.001). (Figure 1b) Differences in pre and post-
transplant occupational and income status remained significant when stratified by survival cohort 
(<2 yrs, 2<6 yrs, 6<10 yrs, >=10 yrs).  
Quality of life (QoL) measured by the FACT-BMT (Version 4) demonstrated high internal consistency, 
with Cronbach's alpha for the test scale of 0.83 (Table 5).  The correlation between subscale and 
summary FACT-BMT test scores was highest for functional well-being (correlation coefficient = 0.89) 
and lowest for social well-being (correlation coefficient= 0.63). Across FACT-BMT domains, social 
well being further demonstrated the lowest reliability, with removal of this item increasing test scale 
reliability (from 0.83 to 0.85). Mean QoL scores showed no significant differences when stratified by 
years from transplant (p=0.12).  Lee cGVHD score showed a negative correlation with QoL measures 
(Pearson’s correlation coefficient = -0.63 ).  
In total 364 (86%) of 441 patients had an underlying cancer diagnosis at transplantation. Median fear 
of cancer recurrence (FoCR) score in those within 2 years of transplant was 15 (IQR 12, 19; range 5-
24) as compared to 13 (IQR 10, 16; Range: 5-25) for those who were late transplant survivors 
(P<0.001). 
There were some differences between genders in personal growth following allo-HSCT measured by 
PTGI; females exhibited greater growth than males in relationship with others (P<0.001), personal 
strength (P<0.001) and spiritual growth (P<0.001).  
Discussion 
This study is the largest and most comprehensive assessment of allo-HSCT survivorship in a 
contemporary Australian cohort. The results reveal a high incidence and broad range of physiological 
and psycho-social complications that adversely affect the health and functional status of survivors.  
The incidence of cGVHD was 69% for the studied group, which is within reported ranges in the 
literature despite an older cohort (median age 54), utilization of unrelated and mismatched donors 
(43.1%), and PBSC (86.4%). (1, 24, 25) 
Chronic physiological effects were common with 57% of the study group reporting two or more 
active medical co-morbidities. Importantly, cGVHD increased the odds of chronic medical and 
psychological sequelae, particularly osteoporosis/osteopenia, diabetes mellitus, cataracts, recurrent 
respiratory tract infections and anxiety. 
After cGvHD, sexual dysfunction was the most adversely affected domain following allo-HSCT 
reported by allo-HSCT survivors in this study. Over 95% of study participants provided insight into 
resumption of sexual activity following allo-HSCT, which was similar between males and females 
(69%). Approximately 60% of respondents reported sexual difficulties post-transplant (66.4% 
females, 51.5% males). As sexual dysfunction likely results from multiple chronic physical and 
psychological comorbidities our results suggest the need for a comprehensive multidisciplinary 
approach to prevention and management that includes education of allo-HSCT candidates and 
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partners prior to transplantation, ongoing assessment and counselling post-transplant and early 
specialist referral to prevent delayed diagnosis and treatment.   
The psychosocial impact of allo-HSCT was profound, affected by loss of employment and reduced 
income. Social re-integration was modest, with significant underemployment, unemployment and 
non-return to work (most often as a consequence of chronic ill-health), and increase in the number 
of survivors in the lowest income bracket. While strategies aimed at the prevention and treatment 
of chronic physical and psychological complications of allo-HSCT may improve social re-integration 
and minimize financial disenfranchisement, these are unlikely to completely ameliorate the 
psychosocial impacts of allo-HSCT. These results suggest potential transplant recipients should 
receive pre- and post-transplant counselling and be directed to seek appropriate assistance to 
reorganize their finances and assets. This study shows that “financial toxicity” is an adverse effect of 
allo-HSCT that should be considered on par with other long-term effects. Additionally, financial 
stress may contribute to non-adherence and lifestyle modifications that are detrimental to a 
survivor’s quality of life. (26) A graded, objective measure of financial toxicity is needed. (27, 28)  
Improvements in vaccination and up-take of screening following allo-HSCT are urgently needed. Less 
than a third of respondents had completed the recommended post-transplant vaccination schedule, 
and this is reflected by a high incidence of vaccine-preventable diseases (42%). These alarming 
statistics suggests that current systems are resulting in an unacceptably high “miss” rate and 
arguably mandate a change in vaccination promotion and delivery. Furthermore, national 
immunisation guidelines for allo-HSCT and other transplant recipients have been available and 
published within the most recent editions of the national Australian Immunisation handbook that is 
easily accessible to the public and health care workers. In this regard, it is noteworthy that in 
multivariate analysis, demographic differences and the presence of cGVHD had no effect on 
vaccination uptake, whereas those who had an allo-HSCT for over 2 years were 12 times more likely 
to be vaccinated. The results suggest that there are barriers to vaccination during the first 2 years 
post-transplant and that these are unrelated to the presence or severity of cGvHD or to baseline 
demographics. Of those who had received vaccinations (31% complete, 51% partial), three quarters 
were administered by general practitioners – an important reminder both of the importance of 
primary/local healthcare providers in the long-term care of allo-HSCT recipients and of the need for 
ongoing communication with, and education of, health practitioners involved in the care of 
survivors. (29, 30) That said, the fact that most allo-HSCT survivors receive post-transplant care 
through their transplant centre and express a preference for centrally coordinated care suggests 
that long-term follow-up clinics may need to provide post-transplant vaccination service, at the very 
least for survivors who do not have a general practitioner. 
Other health screenings assessed in the study were also suboptimal. Only 52% of respondents had 
routine skin checks, a disappointing response given the high incidence of skin malignancies following 
allo-HSCT and the high background incidence of both melanoma and non-melanoma cancers in 
Australia. (31, 32) Likewise, only 63% and 53% respectively of female survivors of allo-HSCT had had 
recommended PAP smear cervical carcinoma screening and 53% screening mammography. Just two 
thirds of survivors have regular dental/oral reviews; older age, higher income and residing in a 
metropolitan area were predictors of regular dental review. Non-attendance was reported to be due 
to finances by a third, and due to thinking that dental reviews were unnecessary by another third. 
There is an urgent need for education about the long-term effects of oral health following allo-HSCT. 
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These results may also evidence systemic failings as it is well recognised that there are a number of 
financial and structural barriers that prevent Australians accessing affordable dental care; with a 
2010 Australian Institute of Health and Research survey reporting that 30% of adults avoided 
dentists due to costs (http://www.aihw.gov.au/dental/cost/). While there are public dental services 
in New South Wales, and some transplant centres have access to hospital-based dental clinics, the 
waiting times are long and the location inconvenient for many survivors  
Summarily, these results suggest that survivors with cGVHD should receive additional psychological 
intervention, dedicated screening and aggressive prevention and treatment of 
osteoporosis/ostepenia and diabetes mellitus. Other groups identified in need of additional focus to 
reinforce and improve health screening are younger transplant recipients, those with less education, 
those in the “early” post-transplant period and survivors residing in rural/regional Australia. 
While the large number of participating survivors, high response rate, multi-centre cohort and 
comprehensive assessment makes it likely that these results represent an accurate account of the 
experience of contemporary survivors of allo-HSCT in Australia, there are a number of factors that 
may limit the generalizability of these results to allo-HSCT survivors in other countries and settings.  
First, despite the high response rate (76%), participation was incomplete resulting in possible 
participation bias. Second, the study was a cross-sectional study that included only those alive at 
study recruitment, thereby excluding those who may have died because of post-transplant 
complications – which may have been more rapidly progressive or highly lethal. Third, the use of a 
questionnaire as the research methodology has well-recognised inherent limitations, including recall 
and misclassification biases that, despite piloting, the use of validated instruments and simple 
English, could potentially limit self-reported response internal validity. Misclassification biases may 
go in either directions, thereby over-estimating or under-estimating effects.   Fourth, the veracity of 
participants’ responses was not compared with medical records, which may compromise factorial 
validity. Fifth, the questionnaire could not distinguish between the effects of cGVHD from 
complications of its treatment – a limitation that may be of no consequence to the study of chronic 
health, as most survivors with cGVHD require prolonged immunosuppression. Sixth, the respondents 
to this study were disproportionately white/Caucasians (86.9%), thus limiting the ability to 
generalize to other ethnic groups.  
This study provides the largest and most comprehensive account of the incidence and range of late 
complications following allo-HSCT in a contemporary population of Australian survivors. For the 
most part, the incidence of cGVHD and chronic post-transplant comorbidities were similar to that 
reported in available literature. (6, 24, 25) Our results also reveal the extent to which allo-HSCT 
transforms the lives of survivors – causing psychological, social and sexual dysfunction, financial 
insecurity and occupational vulnerability in many survivors. Perhaps most worryingly, this study also 
suggests that the care of allo-HSCT recipients is deficient in many ways, with suboptimal health 
screening, dental care and vaccination uptake as areas of unmet needs in Australian allo-HSCT 
survivors. Addressing these deficiencies will clearly require a multidisciplinary approach and may 
necessitate changes in the delivery of healthcare to Australian patients. Extrapolating from 
paediatric experiences (33-35) and overseas models (such as the Fred Hutchison Cancer Reseach 
Centre/Seattle Cancer Care Alliance or MD Anderson Cancer Centre in the United States) (30), 
centralized co-ordination through a long-term follow-up survivor’s clinic may best address 
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inadequacies of the current system. Such structures may avoid fragmentation of services and 
provides continuity of care, both of which are essential to address complex problems such as sexual 
dysfunction and adherence/compliance with health promotion.  But the success of such a service 
cannot be assumed and would need to be the focus of ongoing research. Irrespective of what model 
of care proves to be most effective, the results of this study make clear that as allo-HSCT recipients 
live longer, the focus of care and resources must proportionately shift to improving their quality of 
life and optimising their experience of survivorship.  
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 Tables and Figure 
Table 1; Survivor Demographics and Transplant Characteristics. This table summarizes 
characteristics of study participants.  
Characteristic (number of respondents) number (per cent)   
Gender (n=441) n (%)   
Male 250 (56.7%)   
Female 191 (43.3%)   
Age (n=441)     
median 49   
19-29 30  (6.8%)   
30-39 49 (11.1%)   
40-49 83 (18.8%)   
50-59 130 (29.5%)   
60-69 127 (28.8%)   
>70 22 (5.0%)   
Ethnicity (n=372)     
Australian/European 323 (86.8%)   
Indigenous Australian 2 (0.5%)   
Asian 30 (8.1%)   
Middle Eastern 7 (1.9%)   
Other 10 (2.7%)   
Residential Location (n=431)     
Major City 311 (72.2%)   
Inner Regional 85 (19.7%)   
Outer Regional 31 (7.2%)   
Remote  4 (0.9%)   
Years since transplant (n=441)     
median 5   
< 2yrs 58 (13.2%)   
2 to <6 yrs 204 (46.3%)   
6 to <10 yrs 117 (26.5%)   
>=10 <15  yrs 62 (14.1%)   
Numbers by Transplant Year (N=441)     
2000-2005 136 (30.8%)   
2006-2012 305 (69.1%)   
Transplant recipients by centre (N=441)     
Centre A (Westmead) 193 (43.8%)   
Centre B (St Vincent's) 124 (28.1%)   
Centre C (Royal North Shore) 72 (16.3%)   
Centre D (Royal Prince Alfred) 52 (11.8%)   
Underlying diagnosis  (N=423)     
AML/ALL 169/57 =226 (53.4%)   
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CML 21 (5.0%)   
CLL 19 (4.5%)   
SAA 16 (3.8%)   
NHL 79(18.7%)   
HL 5 (1.2%)   
MM 14(3.3%)   
MDS/Myeloproliferative disorder 39 (9.2%)   
Other (Unspecified) 4 (0.9%)   
Remission status (N=405)     
CR1 /CR2 271 (66.9%)   
>CR2 22 (5.4%)   
Chronic Phase 18 (4.4%)   
Accelerated Phase and blast crisis 3 (0.7 %)   
Refractory 22 (5.4%)   
Partial remission 23 (5.7%)   
Other 46 (11.4%)   
Donor type (N=441)     
Sibling 250 (56.9%)   
Haploidentical 10 (2.3%)   
Matched Unrelated 158 (36%)   
Mismatched Unrelated 21 (4.8%)   
Stem Cell Source (N=441)     
Bone Marrow 48 (10.9%)   
PBSCT 381 (86.4%)   
Cord 12 (2.7%)   
Conditioning (N=439)     
Myeloablative 214 (48.7%)   
TBI containing 101 (47.2%)   
Bu/Cy 79 (36.9%)   
Cy/TBI 99(46.3%)   
Bu/Flu 28 (13.1%)   
Cy/ATGAM 5(2.3%)   
Cy/Flu/ATGAM 1(0.5%)   
Bu/Flu/Thymoglobulin/TBI 1(0.5%)   
Etop/TBI 1(0.5%)   
Reduced intensity 225 (51.3%)    
TBI containing 26 (11.6%)   
Flu/Cy 24(10.7%)   
Flu/Cy/TBI 14(6.2%)   
Flu/Mel 98(43.6%)   
FLAMSA 1(0.4%)   
Flu/BCNU/Mel/ATG 42(18.7%)   
Flu/TBI 12(5.3%)   
Other(unspecified) 34(15.1%)   
GVHD prophylaxis (N=440)     
CSA+ MTX 157 (35.7%)   
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CSA+MTX+pred 166 (37.7%)   
CSA+MMF+pred 4(0.9%)   
MTX+pred 10 (2.3%)   
Tacro+MTX 0 (0.2%)   
CSA+Tacro+MMF 9(2.0%)   
MMF+MTX 0   
Other(unspecified) 94 (21.4%)   
T-cell Depletion (N=426)      
Yes 122 (28.6%)   
ATGAM/ATG(Fresnius/Thymoglobulin)  113 (92.6%)   
Alemtuzumab (Campath) 4 (3.2%)   
No 304 (71.4%)   
Not reported 5 (4.1%)   
   Abbreviations: AML acute myeloid leukaemia; ALL acute lymphoblastic leukaemia; CML chronic 
myelogenous leukaemia; CLL chronic lymphocytic leukaemia; SAA severe aplastic anaemia; NHL non-
Hodgkin's lymphoma; HL Hodgkin's Lymphoma; MM multiple myeloma; MDS myelodysplastic 
syndrome; CR complete remission; PBSCT peripheral blood stem cell transplantation; TBI total body 
irradiation; Bu busulfan; Cy cyclophosphamide; Flu fludarabine; ATGAM anti-thymocyte globulin, 
equine; Etop etoposide; Mel melphalan; FLAMSA  fludarabine, cytarabine, amsacrine; BCNU 
carmustine; GVHD chronic graft versus host disease; CSA cyclosporine; MTX methotrexate; Pred 
prednisolone; tacro tacrolimus; MMF mycophenolate mofotil  
 
Table 2; Chronic Graft versus Host Disease (cGVHD). This table summarizes the incidence, extent 
and severity of cGVHD in study participants. For the Lee cGVHD score, median and interquartile 
range are provided.  
cGVHD Characteristic (number of respondents) Number (per cent) 
cGVHD (n=434) 301 (69.3%) 
Male (n=246) 177 (72%) 
Female (n=188) 124(66.0%) 
cGVHD by age group (N=434)   
19-29 (n=30) 19 (63.3%) 
30-39 (n=49) 31 (63.3%) 
40-49 (n=81) 58 (71.6%) 
50-59 (n=129) 89 (69%) 
60-69 (n=123) 85 (69.1%) 
>=70  (n=22) 19 (86.4%) 
cGVHD organ involvement (n=434)                         
Skin 203 (46.7%) 
Eyes 153 (35.2%) 
Lungs 79 (18.2%) 
Mouth 155 (35.7%) 
Liver 99 (22.8%) 
Stomach & Intestines 61 (14.1%) 
Nails 53 (12.2%) 
Vagina(females) 41/188 (21.8%) 
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Penis(Males) 13/ 246 (5.3%) 
Muscle/ joints 64 (14.5%) 
Other organ(not specified) 18 (4.1%) 
Not sure 10(2.3%) 
Lee GVHD scores (median, IQR, range)   
Skin score 10   (IQR: 0, 25; Range 0-100) 
Eye score 33 (IQR: 8 , 75; Range 0-100) 
Mouth score 0 (IQR: 0, 25: Range 0-100) 
Nutrition score 0 (IQR:0, 5: Range 0-100) 
Lung score 5 (IQR: 0, 15: Range 0-70) 
Psych score 17 (IQR: 0, 33: Range 0-100) 
Energy score 32 (IQR: 17, 50: Range 0-100) 
Global score 19  (IQR 9, 30: Range 0-77) 
Vulvovaginal symptoms (females) 45 (46.8%) 
GVHD patient global ratings of symptoms (N=111)   
None 18 (16.2%) 
Mild  57(51.4%) 
Moderate 31(27.9%) 
Severe 5 (4.5%) 
Symptom severity at study compared to 1 month ago   
Very much better 40 (15.2%) 
Moderately better 21(7.9%) 
A little better 34(12.9%) 
About the same 149(56.5%) 
A little worse 13 (4.9%) 
Moderately worse 4(1.5%) 
Very much worse 13 (0.8%) 
 
Table 3; Chronic Co-morbidities and Secondary Malignancies. This table summarizes the 
physiological (including malignant) and psychological chronic co-morbidities experienced by study 
participants, reported as a percentage of respondents.  
Table 3   
Co-morbidity (number of respondents)  Number affected (percentage) 
Chronic Medical Morbidities   
Hypothyrodism (n=391) 16 (4.1%) 
Hyperthyroidism (n=390) 5 (1.3%) 
Diabetes mellitus (n=398) 57 (14.3%) 
Any of the above (n=395) 75 (19.0%) 
Osteporosis/Osteopaenia (n=399) 116 (29.1%) 
Avascular necrosis (n=389) 14 (3.6%) 
Any spinal/hip fracture (n=392) 17 (4.3%) 
Hypertension (n=409) 118 (28.9%) 
hypercholesterolaemia (n=402) 96 (23.9%) 
Cataracts (n=409) 118 (28.9%) 
Iron Overload (n=403) 131(32.5%) 
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Recurrent upper respiratory tract infections (n=402) 92(22.9%) 
Malignancies   
Skin cancer (n=404) 93 (23%) 
Basal Cell Carcinoma (BCC) 41 (44%) 
Squamous Cell Carcinoma (SCC) 14 (15%) 
Melanoma 5 (6%) 
Combined Mixed 17 (18%) 
BCC+SCC 14(15%) 
BCC+Melanoma 2 (2%) 
SCC+Melanoma 1(1%) 
Unspecified/unknown 16(17%) 
Oral Cancers (n=392) 6 (1.5%) 
Other Malignancies (n=370) 18 (4.9%) 
Urological(prostate and/or bladder)  5 (27%)‡ 
Breast 2 (11%) 
Bowel 1 (6%) 
Ovarian 1 (6%) 
Head (unspecified) 1 (6%) 
Myeloid sarcoma 1 (6%) 
Haematological - Relapsed Disease 2(11%)  
Haematological - Secondary malignancy 5 (27%) 
Depression and Anxiety, Self Reported    
Self reported Depression (N=407) 95 (23.3%) 
Self reported  Anxiety or Depression (N=403) 83 (20.6%) 
Self reported Anxiety&/or Depression (N=409) 118 (28.8%) 
Depression Anxiety & Stress Scores (DASS21) Median (IQR;Range) n=438 
Depression Score  4 (2, 14; 0-40) 
Normal (0-9) 287(65.2%) 
Mild (10-13) 41 (9.4%) 
Moderate (14-20) 65 (14.8%) 
Severe (21-27) 23 (5.2%) 
Extremely Severe (28+) 22 (5%) 
Anxiety Score Median (IQR, Range) n=438 4(2,10; 0-42) 
Normal (0-7) 280 (63.7%) 
Mild (8-9) 31 (7.1%) 
Moderate (10-14) 58 (13.2%) 
Severe (15-19) 23(5.2%) 
Very Severe (20+) 46(10.5%) 
Stress Score (Median, IQR, Range) n=437 8 (2,16; 0-42) 
Normal (0-14) 315 (72.1%) 
Mild (15-18) 35 (8.0%) 
Moderate (19-25) 40 (9.1%) 
Severe (26-33) 34(7.8%) 
Very Severe (34+) 13 (3.0%) 
Total DASS 21 score Median (IQR, Range) n=437 20 (8, 40; 0-118) 
Abbreviations: DASS The Depression Anxiety Stress Scales, see reference 37; IQR inter-
quartile range 
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‡ 3 prostate, 1 bladder, 1 bladder + prostate   
§ 2 non-Hodgkin lymphomas (primary = acute myeloid leukaemia, severe aplastic anaemia); 2 
Hodgkin Lymphomas (Primary = NHL); 1 post transplant lymphoproliferative disease 
§§1 Relapsed AML; 1 relapsed Mantle Cell Lymphoma   
 
Table 4; Health checks, cancer screening and vaccination. The number who takes up health checks, 
screening and vaccination, and as a percentage of respondents are provided.  
Table 4 
 Health Screen/Promotion (number of respondents) Uptake (percentage) 
Skin Checks (n=436) 228 (52.3%) 
Colorectal Carcinomal Screening (n=432) 140(32.4%) 
Cervical Carcinoma Screening (n=186) 118 (63.4%) 
Breast Carcinoma Screening (n=184) 98 (53.3%) 
Prostate Checks (n=246) 89 (36.2%) 
Regular Dental and Oral Reviews (n=436) 288 (66.1%) 
Vaccination Uptake Status* (n=428)   
Complete 31.80% 
Partial 57.90% 
No vaccine 7.20% 
Uncertain 3% 
Vaccination   
    Diphtheria, Tetanus, Pertussis (n= 419) 303 (72.3%) 
1 to <2 yrs from allo-HSCT 36/56(64.3%) 
2<6 yrs from allo-HSCT 15/82(18.3%) 
6<10 yrs from allo-HSCT 75/107(70.1%) 
≥10 yrs from allo-HSCT 40/57(70.2%) 
    Polio (n=416) 280(67.3%) 
1 to <2 yrs from allo-HSCT 36/58(62.1%) 
2<6 yrs from allo-HSCT 15/82(18.3%) 
6<10 yrs from allo-HSCT 65/106 (61.3%) 
≥10 yrs from allo-HSCT 32/55(58.2%) 
Haemophilus Influenza (n=405) 229(56.5%) 
1 to <2 yrs from allo-HSCT 30/53(56.6%) 
2<6 yrs from allo-HSCT 15/82(18.3%) 
6<10 yrs from allo-HSCT 53/104(51.0%) 
≥10 yrs from allo-HSCT 17/52(32.7%) 
Hepatitis B (n=414) 270 (65.2%) 
1 to <2 yrs from allo-HSCT 35/56(62.5%) 
2<6 yrs from allo-HSCT 15/82(18.3%) 
6<10 yrs from allo-HSCT 62/105(59.1%) 
≥10 yrs from allo-HSCT 29/54(53.7%) 
Pneumococcal vaccine for Streptococcus 
pneumoniae (n=402) 
226 (56.2%) 
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1 to <2 yrs from allo-HSCT 29/53(54.7%) 
2<6 yrs from allo-HSCT 15/82(18.3%) 
6<10 yrs from allo-HSCT 51/106(48.1%) 
≥10 yrs from allo-HSCT 28/53(52.8%) 
Influenza (n=426) 349 (81.9%) 
1 to <2 yrs from allo-HSCT 40/56(71.4%) 
2<6 yrs from allo-HSCT 15/82(18.3%) 
6<10 yrs from allo-HSCT 95/113(84.1%) 
≥10 yrs from allo-HSCT 48/58(82.8%) 
Meningococcal Vaccine for Neisseria menigitides 
(n=407) 
201(49.3%) 
1 to <2 yrs from allo-HSCT 31/54(57.4%) 
2<6 yrs from allo-HSCT 15/82(18.3%) 
6<10 yrs from allo-HSCT 47/103(45.6%) 
≥10 yrs from allo-HSCT 16/55(29.1%) 
Measles, Mumps, Rubella (n=409) 226(55.3%) 
1 to <2 yrs from allo-HSCT 16/52(30.8%) 
2<6 yrs from allo-HSCT 15/82(18.3%) 
6<10 yrs from allo-HSCT 66/106(62.2%) 
≥10 yrs from allo-HSCT 31/57(54.4%) 
    Varicella (n=399) 106(26.6%) 
1 to <2 yrs from allo-HSCT 11/53(20.7%) 
2<6 yrs from allo-HSCT 15/82(18.3%) 
6<10 yrs from allo-HSCT 28/100(28%) 
≥10 yrs from allo-HSCT 8/53(15.1%) 
 Human Papillomavirus (females, n=174) 26 (14.9%) 
1 to <2 yrs from allo-HSCT 1/20 (5%) 
2<6 yrs from allo-HSCT 15/82(18.3%) 
6<10 yrs from allo-HSCT 9/48(18.7%) 
≥10 yrs from allo-HSCT 1/24(4.2%) 
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Table 5; Quality of Life - FACT BMT. Results of the FACT BMT are summarized. Mean, standard deviation and Cronbach alpha for all respondents, and 
respondents classified into time periods post allo-HSCT are provided 
  ALL survivors < 2 yrs post allo-HSCT 2 < 6 yrs post allo-HSCT 6 < 10 yrs post allo-HSCT ≥ 10yrs-14 yrs post allo-HSCT 
  Mean (SD) 
Cronbach 
alpha 
Mean (SD) 
Cronbach 
alpha 
Mean (SD) 
Cronbach 
alpha 
Mean (SD) 
Cronbach 
alpha 
Mean (SD) 
Cronbach 
alpha 
Physical well-being (PWB) 22.4(5.4) 0.9 21.2 (5.9) 0.91 22.4(5.4) 0.9 22.7 (5.1) 0.91 22.8(5.2) 0.9 
Social well-being (SWB) 20.0(5.6) 0.91 20.1  (5.6) 0.92 20.5(5.6) 0.91 19.9(5.4) 0.91 19.5(6.2) 0.91 
Emotional well-
being(EWB) 
16.3 (3.6) 0.91 15.5(3.6) 0.92 16.4(3.4) 0.91 16.7(3.5) 0.91 15.9 (4.8) 0.91 
Functional well-being 
(FWB) 
19.3 (6.5) 0.9 17.5 (6.8) 0.9 19.4 (6.3) 0.89 20.0(6.6) 0.89 19.1(6.1) 0.89 
BMT score (BMTS) 27.8 (6.3) 0.9 25.7(7.8) 0.9 27.6(6.1) 9.9 28.5(5.7) 0.9 28.9(5.7) 0.9 
FACT G 
(PWB+SWB+EWB+FWB) 
78.3 (16.2) 0.87 74.4(17.8) 0.87 78.7(16.1) 0.87 79.8(15.8) 0.87 77.8(15.8) 0.86 
FACT BMT total score 
106.0 (21.5) 0.89 100.0 (24.8) 0.89 106.3(21.1) 0.88 108.3(20.6) 0.87 106.7(20.1) 0.87 
(FACTG + BMTS) 
FACT BMT Trial Outcome 
Index 69.5 (16.1) 0.87 64.4(18.8) 0.88 69.4(15.9) 0.87 71.4(15.3) 0.87 
70.9 
0.87 
PWB + FWB +BMTS -14.9 
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Figure 1a and 1b; Social changes following allo-HSCT; a) income b) work status. Change in income 
as a percentage following allo-HSCT is shown in Figure 1a. Change in employment status as a 
percentage following allo-HSCT is shown in Figure 1b.  
Figure 1a 
 
Figure 1b 
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Supplementary Table 1; Infectious Diseases. This table summarizes the number of study 
participants who reports infectious complications, and expressed as a percentage of respondents.  
The median age (and range), and time from allo-HSCT are provided.   
Supplementary Table 1       
Infection (respondents) n (%) Median Age 
Years post allo-
HSCT (range) 
Recurrent colds (n=402) 92 (22.9%) 52 (19-74) 6 (1-14) 
Influenza (n=419) 161 (38.4%) 54 (19-79) 6(1-14) 
Pertussis (412) 11 (2.7%) 65(43-73) 7(4-11) 
Strep. pneumoniae pneumonia (n=415) 21 (5.1%) 62(30-73) 8(1-13) 
Haemophilus influenzae pneumonia (n=411) 12 (2.9%) 52(29-68) 3(<2-8) 
Mycobacterium tuberculosis (n=412) 3 (0.7%) 70(51,71) 7(4-10) 
Hepatitis A (n=414) 1 (0.2%) 34 yrs 9yrs 
Hepatitis B (n=413) 6 (1.5%) 60(47-66) 5(<2, 11) 
Hepatitis C (n=414) 4 (0.9%) 60(52-62) 6(<2,14) 
Primary Varicella Zoster (Chicken Pox) 
(n=416) 
19 (4.6%) 56(27-69) 5(<2-14) 
Zoster/shingles (n=420) 117 (27.9%) 56(21-74) 6(<2-14) 
Measles (n=413) 3 (0.7%) 61(40,70) 2(3,11) 
Mumps (n=414) 2 (0.5%) 61,70 3, 11 
Rubella (n=413) 2 (0.5%) 61,70 3,11 
Pap smear abnormalities (n=184 females) 18 (9.8%) 42(22-65) 8(<2, 14) 
Genital warts , Human papilloma virus     
 
Males (n=230) 12 (5.2%) 55(29-70) 7(3-13) 
Female (n=182) 3 (1.6%) 50(30,58) 9(3,11) 
Fungal Infection (n=408) 62 (15.2%) 55(21-73) 5(<2-14) 
    Mucocutaneous (thrush/candida/skin) 29/408 (7.1%)   
 
    Aspergillosis/ Lung/sinus 12 (2.9%)   
 
    Onychomycosis (nails) 7 (11.3%)   
 
    Invasive mycosis (prosthetic valve) 1 (1.6%)   
 
    Not specified 14 (1.9%)   
 Vaccine-preventable infections, excluding 
influenza (n=441) 
47 (10.6%) 
  
 Vaccine-preventable infecitons, including 
influenza (n=441) 184 (41.7%)   
         
* with non-live attenuated vaccines (Any of Pertussis, Haemophilus, Pneumococcus, meningococcus, Hep B)   
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Supplementary Table 2; cGVHD and chronic comorbidities. This table compares the presence of 
chronic comorbidities between survivors with and without cGVHD. The numbers affected, odds 
ratio (OR), confidence interval and test statistic are provided 
Chronic Morbidity 
cGVHD 
(n=301) 
No cGVHD 
(n=133) 
OR (95% CI) 
P value 
 Hypothyroidsism 10 6 1.85(1.10, 3.19) 0.01 
 Hyperthyroidism 4 1 1.86(0.18, 92.7)  0.57 
 Diabetes 46 11 2.10(1.01, 4.64)  0.03 
 Osteoporosis/ 
osteopaenia 
90 26 1.85 (1.10, 3.19)  
0.01 
 Avascular necrosis 11 3 1.74(0.45, 9.87) 0.4 
 Hypertension 86 32 1.33 (0.81, 2.23) 0.23 
 Hypercholesterolaemia 73 23 1.58 (0.91, 2.81) 0.09 
 Cataracts 93 23 2.26(1.32, 3.98) 0.001 
 Iron overload 97 32 1.58 (0.96, 2.63) 0.06 
 Recurrent Upper 
Respiratory Tract 
Infection 
72 20 1.86 (1.05, 3.41) 
0.02 
 Depression 73 22 1.70(0.98, 3.04)  0.049 
 Anxiety 65 18 1.86(1.02, 3.50)  0.03 
 
      abbreviations: 
cGVHD=chronic graft 
versus host 
diseaseOR=odds ratio, 
CI=confidence interval 
      
Supplementary Table 3; Medications. The number of participants who are prescribed individual 
drugs are listed, expressed as a percentage of respondents and further sub-divided into time 
periods post allo-HSCT. The table also includes the number of medications respondents are 
prescribed.  
Medications 
 
Number (%)  
(N=441) 
Years since transplant 
 
<2 years 
(n=58) 
2<6 years 
(n=204) 
6<10 yrs 
(n=117) 
≥ 10 yrs 
(n=62) 
          
Anti-infectives           
Penicillin 87 (19.7%) 23 (39.7%) 42 (20.6%) 15 (12.8%) 7(11.3%) 
Bactrim/septrim 127 (28.8%) 40 (68.9%) 61 (29.9%) 20 (17.1%) 6 (9.7%) 
Aciclovir/valacyclovir 120 (27.2%) 35 (60.3%) 61 (29.9%) 20 (17.1%) 4 (6.4%) 
Azole antifungal 53 (12.0%) 13 (22.4%) 25 (12.2%) 11 (9.4%) 4 (6.4%) 
Immunosuppression   
    
Prednisolone 127 (28.8%) 26 (44.8%) 62 (30.4%) 26 (22.2%) 13 (21%) 
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CSA/Tacro/MMF 102 (23.1%) 26 (44.8%) 51 (25%) 17 (14.5%) 8 (12.9%) 
Cardiovascular   
    
Hypolipidaemic 75 (17.0%) 7 (12.1%) 24 (11.8%) 29(24.8%) 15 (24.2%) 
Antihypertensive  110 (24.9%) 13 (22.4%) 37 (18.1%) 33 (28.2%) 27 (43.5%) 
Bone disease   
    
Bisphosphonate 69 (15.6%) 7 (12.1%) 34 (16.7%) 19 (16.2%) 9 (14.5%) 
Vitamin D 240 (54.4%) 32(55.2%) 123(60.3%) 56 (47.9%) 29(46.8%) 
Calcium 204 (46.3%) 25 (43.1%) 107 (52.4%) 49 (41.9%) 23 (37.1%) 
Psychotropics   
    
Anti-anxiolytic 28(6.3%) 7 (12.1%) 10 (4.9%) 6 (5.1%) 5 (8.1%) 
Antidepressant 52 (11.8%) 6 (10.3%) 22 (10.8%) 17 (14.5%) 7(11.3%) 
Sleeping 
tablet/sedative 
47 (10.7%) 9 (15.5%) 21 (10.3%) 11 (9.4%) 6 (9.7%) 
Iron overload   
    
Chelator 10(2.3%) 3 (5.2%) 5 (2.4%) 2 (1.7%) 0 
Hormonal therapy   
    
Hormone 
replacement/oral 
contraceptive 
(females) 
50/191 (26.2%) 3/22 (13.6%) 23/89(25.8%) 
14/52 
(26.9%) 
10/28(35.7%) 
Hormone replacement 
(males) 
14/250 (5.6%) 3/36(8.3%) 5/115(4.3%) 3/65(4.6%) 3/34(8.8%) 
Number of 
Medications   
    1 13% 
    2 14% 
    3 16% 
    4 10% 
    5 10% 
     ≥ 6 21% 
    
      Abbreviations; CSA cyclosporine; tacro tacrolimus; MMF mycophenolate 
mofotil  
   
 
 
 
